Belančić, A.; Mas, P.; Miletić, L.; Kovačić Bytyqi, B.; Vitezić, D.
Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance. J. Clin. Med. 2025, 14, 3173.
https://doi.org/10.3390/jcm14093173
AMA Style
Belančić A, Mas P, Miletić L, Kovačić Bytyqi B, Vitezić D.
Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance. Journal of Clinical Medicine. 2025; 14(9):3173.
https://doi.org/10.3390/jcm14093173
Chicago/Turabian Style
Belančić, Andrej, Petar Mas, Lara Miletić, Barbara Kovačić Bytyqi, and Dinko Vitezić.
2025. "Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance" Journal of Clinical Medicine 14, no. 9: 3173.
https://doi.org/10.3390/jcm14093173
APA Style
Belančić, A., Mas, P., Miletić, L., Kovačić Bytyqi, B., & Vitezić, D.
(2025). Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance. Journal of Clinical Medicine, 14(9), 3173.
https://doi.org/10.3390/jcm14093173